NeuroMab™ Anti-CXCL12 BBB Shuttle Antibody(NRZP-1022-ZP3789)
- Host Species:
- Mouse
- Species Reactivity:
- Human
- Applications:
- In Vitro; In Vivo; Block
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryDescription
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.
Species Reactivity
Clonality
Host Species
Isotype
Applications
Relevant Diseases
Storage
Research Use Only
Target
Official Name
Full Name
Alternative Names
Figure 1. Anti-CXCL12 antibody inhibits cancer cell migration.
Transwell migration of fluorescently labeled TOV-21G cells into CXCL12 was quantified using fluorescence scanning. 114_3H1 (labeled 114_3H01) and 113_1H12 IgG titrated from 0.39-500 nM were mixed with 80 ng/ml (10 nM) human CXCL12 in the lower chamber to test the effect of these antibodies on CXCL12-induced migration. Anti-lysozyme antibody (500 nM) was used as an isotype control. All error bars represent standard deviation.
Figure 2. Anti-CXCL12 antibody inhibits angiogenesis.
Human umbilical vein endothelial cells (HUVEC) were seeded onto fibroblasts grown for 6 days on gelatin-coated chamber slides. These two cell types were co-cultured for 7 days in medium containing VEGF and lead anti-CXCL12 antibodies 114_3H1 and 113_1H12. IgG bound to lysozyme (nonspecific IgG) was used as an isotype control for the assay (Panel A). After 7 days of co-culture, cells were stained for platelet/endothelial adhesion molecule-1 (PECAM-1, an angiogenic marker) to visualize tubule formation and branching by light microscopy. Use AngioSys image analysis software to calculate the total number of tubules and the number of branch connections.
Figure 3 Anti-CXCL12 antibody inhibits angiogenesis.
Human umbilical vein endothelial cells (HUVEC) were seeded onto fibroblasts grown for 6 days on gelatin-coated chamber slides. These two cell types were co-cultured for 7 days in medium containing VEGF and lead anti-CXCL12 antibodies 114_3H1 and 113_1H12. IgG bound to lysozyme (nonspecific IgG) was used as an isotype control for the assay (Panel A). After 7 days of co-culture, cells were stained for platelet/endothelial adhesion molecule-1 (PECAM-1, an angiogenic marker) to visualize tubule formation and branching by light microscopy. Use AngioSys image analysis software to calculate the total number of tubules, total tubule length (Figure 6B).
Figure 4A shows migration trajectories of the results of experiments to determine the effectiveness of antibodies (113_1H12 (hAB113) in the human IgG2 form, 113_1H12 (mAB113) in the chimeric mouse IgG2a form, and 114_3H1 (mAB114) in the chimeric mouse IgG2a form) in the presence of human CXCL12. Case block migration of a murine metastatic melanoma cell line (B16F10).
Figure 4B Migration traces showing the results of experiments to determine the effectiveness of the antibodies (113_1H12 (hAB113) in the human IgG2 form, 113_1H12 (mAB113) in the chimeric mouse IgG2a form, and 114_3H1 (mAB114) in the chimeric mouse IgG2a form) in blocking Migration of a Human Ovarian Cancer Cell Line (TOV-21) in the Presence of Human CXCL12.
Figure 5 Results of cell migration assays based on an in vivo experimental metastasis model of B16F10 melanoma cells CXCR4 is required for migration to the lung and initiation of metastasis.
B16F10 melanoma cells were introduced into C57B1 mice by tail vein injection on day 0, and treatment was initiated on day 1. The treatment regimen was 5 mg/kg of the clinical CXCR4 inhibitor AMD3100 (Plerixafor) twice daily or twice weekly with 10, 15 or 20 mg/kg of the anti-CXCL12 antibody mAb 114 in the chimeric murine IgG2a form -3H1. Mice in the control group were treated twice weekly with 20 mg/kg of the control antibody. All mice were sacrificed on day 14 and the number of metastatic colonies in the lungs was quantified. A level of inhibition comparable to AMD3100 was achieved with 113_1H12 at a dose of 20 mg/kg.
Figure 6 shows the results of an in vitro cell transwell migration assay in which anti-CXCL12 antibodies block the migration of TOV21G cancer cells induced by human CXCL12 in human IgG2 form.
Publications (0)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P2275) (Cat#: NRP-0422-P2275)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1760) (Cat#: NRP-0422-P1760)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1684) (Cat#: NRP-0422-P1684)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- NeuroMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- NeuroMab™ Anti-CD20 Antibody(NRP-0422-P1230) (Cat#: NRP-0422-P1230)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- NeuroMab™ Anti-SEZ6 Antibody(NRP-0422-P517) (Cat#: NRP-0422-P517)
- NeuroMab™ Anti-pTau Antibody(NRP-0422-P1719) (Cat#: NRP-0422-P1719)
- NeuroMab™ Anti-EPHB2 Antibody(NRP-0422-P1220) (Cat#: NRP-0422-P1220)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- Mouse Midbrain Dopaminergic Neuron Cell MN9D (Cat#: NCL2110P059)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Sf295 Human Glioblastoma Cells (Cat#: NCL-2108P180)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- Green Fluorescent BACE1 Cell Lines (Cat#: NCL2110P214)
- iNeu™ Human Midbrain Dopaminergic Neurons (Cat#: NCL-21P6-003)
- Mouse Glioma Cell Line GL261 (Cat#: NCL-2108P28)
- Human Hippocampal Neuron Cells HPPNCs (Cat#: NCL2110P106)
- Rat Microglia Cell Line HAPI, Immortalized (Cat#: NCL2110P015)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Dextran, Cy5 Labeled, 2000 kDa (Cat#: NRZP-0722-ZP22)
- PRV-CAG-EGFP (Cat#: NTA-2011-ZP14)
- Dextran-FITC (Cat#: NTA-2011-ZP110)
- pAAV-EF1a-DIO-EGFP-WPRE (Cat#: NTA-2012AD-P285)
- rAAV-E-SARE-Cre-ERT2-PEST-WPRE-hGH polyA (Cat#: NTA-2010-TT342)
- pAAV-syn-jGCaMP8s-WPRE (Cat#: NTA-2106-P063)
- pAAV-hSyn-DIO-XCaMP-R-WPRE (Cat#: NTA-2012AD-P508)
- AAV-EF1a-mCherry-flex-dtA (Cat#: NRZP-0622-ZP616)
- Dextran-CYanine5.5 (Cat#: NTA-2011-ZP118)
- pAAV-syn-FLEX-jGCaMP8m-WPRE (Cat#: NTA-2106-P065)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)